CLS receives approximately SEK 12.2 million through the exercise of subscription warrants of series TO3

Clinical Laserthermia Systems AB (publ) (“CLS” or the “Company”) carried out a rights issue of units (the “Rights Issue”) and a directed issue of units (the “Directed Issue”) in April 2021. The units issued in the Rights Issue and the Directed Share Issue consisted of shares and subscription warrants from the TO3 (the “Subscription Warrants”) and TO4 series. The exercise period for the TO3 subscription warrants ran during the period from April 11, 2022 until April 25, 2022. In total, 3,484,241 Subscription Warrants were exercised for subscription of new class B shares, corresponding to an exercise rate of approximately 34 percent.

In total, 3,484,241 Subscription Warrants were exercised, corresponding to approximately 34 percent of all the Subscription Warrants issued in the Rights Issue and the Directed Issue, for subscription of in total 3,484,241 class B shares. One Subscription Warrant entitled to subscribe for one new class B share in CLS at a subscription price per share of SEK 3.50. Through the exercise of the Subscription Warrants CLS will thereby receive approximately SEK 12.2 million before issue costs.

Number of shares and share capital

Through the exercise of the Subscription Warrants, the number of shares in CLS will increase by 3,484,241 class B shares, an increase from 65,822,310 shares to 69,306,551 shares, of which 600,000 will be class A shares and 68,706,551 will be class B shares. The share capital increases by approximately SEK 322,292.29 from approximately SEK 6,088,563.71 to approximately SEK 6,410,856. The dilution for existing shareholders who have not exercised any Subscription Warrants amounts to approximately 5 percent, based on the number of shares in CLS after the exercise of the Subscription Warrants.

Advisor
Redeye AB is acting as the financial advisor and Aqurat Fondkommission AB is acting as the issuing institution for the transaction.

For further information, please contact:

Dan J. Mogren, Acting CEO Clinical Laserthermia Systems AB (publ)
Tel: +46 (0)705 90 11 40

Email: dan.mogren@clinicallaser.com

About CLS and TRANBERG

Clinical Laserthermia Systems AB (publ) develops and sells the TRANBERG®|Thermal Therapy Systems, including Thermoguide Workstation and sterile disposables, for minimally invasive treatment of cancer tumors and drug-resistant epilepsy, according to regulatory approvals in the EU and the US. All components of the TRANBERG®|Thermal Therapy Systems have received EU-wide regulatory approval as medical devices (CE-marked class II) for the treatment of soft tissue lesions. CLS is developing its systems to get CE-mark class III for disposable TRANBERG laser applicators to be used in brain as well as expanding the current CE-mark for treatment with imILT®, the Company's interstitial laser thermotherapy for immunostimulatory ablation with potential abscopal effect. CLS is headquartered in Lund and has subsidiaries in Germany, the US and Singapore. CLS is listed on the Nasdaq First North Growth Market under the symbol CLS B. The Certified Advisor (CA) is FNCA Sweden AB, Tel: +46 8 528 00 399. E-mail: info@fnca.se. 

For more information about CLS, please visit the Company's website: www.clinicallaser.se